no news_id given

PortugalPortugal

03.11.2008

Poco Barreto – In mid-August, 60 anti-GMO activists destroyed a field planted with insect-resistant Mon810 maize in Portugal. Near the small Algarve town of Poco Barreto, activists from the “Movimento Verde Eufemia” trampled...

PortugalPortugal

19.08.2008

Lisbon – The international contract research organisation Chiltern sees potential for growth in Portugal. In May, it opened a new office in Lisbon that will be managed by Ricardo Diaz. Over the last two years, numbers of clinical...

PortugalPortugal

19.03.2008

Porto – 164 farmers planted a total of 4,199 hectares of genetically modified maize in Portugal in 2007, according to a report issued by the Portuguese Ministry of Agriculture. That represents a 330% increase compared to 2006,...

PortugalPortugal

22.11.2007

Cantanhede – Biogen Idec (Cambridge, US) and the Portuguese biopark Biocant in the Coimbra region have signed a socalled ‘Sponsored Research Agreement’ worth an undisclosed amount. Under the terms of the agreement, researchers...

Portugal, SpainPortugal

11.07.2007

Oeiras/Navarra – Portuguese antibody and genomics specialist Biotecnol SA and the Spanish university spin-off Digna Biotech will develop a process for manufacturing cardiotrophin-1 (CT-1) for the treatment of ischemic-reperfusion...

PortugalPortugal

11.07.2007

Porto – In September 2005, the Portuguese government established a decree law (No. 160/2005) on the co-existence between genetically modified organisms (GMO), conventional and organic crops. In short, it recommends a minimum...

PortugalPortugal

11.07.2007

Almada – transADVANcis Lda, a consultancy firm for nanotechnology and life sciences executives, has launched a website called www.nanogolive.com. With the new portal, on which anyone from the nanotechnology and life science...

PortugalPortugal

16.05.2007

Porto – Two Portuguese biotech companies have won the national idea contest for bio-entrepreneurs (Concurso de Ideias Bioempreendedor 2006), organized every year by the Portuguese Association of Bioindustries (APBio) and the...

PortugalPortugal

16.03.2007

Port Salvo – Biotrend S.A., developers of high-value compounds based in Lisbon, has closed a second investment round with the public venture capital outfit PME Investimientos, ending with a total investment exceeding 1 million...

PortugalPortugal

16.03.2007

Porto Salvo – Alfama, developers of small molecule drugs, has opened a laboratory in Boston, Massachusetts, in order to achieve US presence. The company will carry out research on the effects of self-developed molecules on...

Displaying results 11 to 20 out of 38

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-portugal/browse/1.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK19.09%
  • PROTHENA PLC (IE)42.69 USD6.86%
  • GW PHARMACEUTICALS (UK)657.00 GBP5.65%

FLOP

  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ACTIVE BIOTECH (S)9.45 SEK-10.85%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • GALAPAGOS (B)51.79 EUR37.8%
  • FLAMEL TECHNOLOGIES (F)19.55 USD36.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK-48.4%
  • CYTOS (CH)0.59 CHF-41.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.88 EUR518.1%
  • WILEX (D)4.11 EUR470.8%
  • ADOCIA (F)67.61 EUR440.4%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • ACTIVE BIOTECH (S)9.45 SEK-72.0%
  • THROMBOGENICS (B)5.33 EUR-70.0%

No liability assumed, Date: 02.06.2015

Current issue

All issues